Earnings Feed
Start Free
Home/Filings/4/0001144204-14-002155
4//SEC Filing

CorMedix Inc. 4

Accession 0001144204-14-002155

$CRMDCIK 0001410098operating
View on SEC.govCompany Profile

Filed

Jan 13, 7:00 PM ET

Accepted

Jan 14, 4:12 PM ET

Size

28.0 KB

Accession

0001144204-14-002155

Insider Transaction Report

Form 4
Period: 2014-01-10
CorMedix Inc.CRMD
Gelbfish Gary A.
Director
Transactions
  • Award

    Stock Option (right to buy)

    2014-01-10$2.02/sh+30,000$60,600→ 30,000 total
    Exercise: $2.02Exp: 2024-01-09→ Common Stock, $0.001 par value per share (30,000 underlying)
  • Award

    Stock Option (right to buy)

    2014-01-10$2.02/sh+200,000$404,000→ 175,000 total
    Exercise: $2.02Exp: 2024-01-09→ Common Stock, $0.01 par value per share (200,000 underlying)
Holdings

  • Common Stock, $0.001 par value per share

    474,382

  • Common Stock, $0.001 par value per share

    (indirect: By Foundation)
    70,872

  • Series C-3 Non-Voting Convertible Preferred Stock

    (indirect: By Trust)
    Exercise: $1.00→ Common Stock, $0.001 par value per share (200,000 underlying)
    20,000

  • Warrant (right to purchase Common Stock)

    Exercise: $0.40From: 2012-09-20Exp: 2017-09-20→ Common Stock, $0.00 par value per share (250,000 underlying)
    250,000

  • Stock Option (right to buy)

    Exercise: $2.10Exp: 2021-01-14→ Common Stock, $0.001 par value per share (30,000 underlying)
    30,000

  • Warrant (right to purchase Common Stock)

    (indirect: By Trust)
    Exercise: $1.25From: 2015-01-08Exp: 2020-01-08→ Common Stock, $0.001 par value per share (100,000 underlying)
    100,000

  • Stock Option (right to buy)

    Exercise: $0.90Exp: 2023-03-20→ Common Stock, $0.001 par value per share (50,000 underlying)
    50,000

  • Stock Option (right to buy)

    Exercise: $0.29Exp: 2022-01-06→ Common Stock, $0.001 par value per share (30,000 underlying)
    30,000

  • Stock Option (right to buy)

    Exercise: $3.13Exp: 2020-03-30→ Common Stock, $0.001 par value per share (20,000 underlying)
    20,000

  • 8% Noteholder Warrants

    Exercise: $3.44Exp: 2016-10-29→ Common Stock, $0.001 par value per share (67,200 underlying)
    67,200

  • 8% Noteholder Warrants

    (indirect: By Foundation)
    Exercise: $3.44Exp: 2016-10-29→ Common Stock, $0.001 par value per share (28,800 underlying)
    28,800

  • Warrant (right to purchase Comm Stock)

    Exercise: $1.25From: 2015-01-08Exp: 2020-01-08→ Common Stock, $0.001 par value per share (150,000 underlying)
    150,000

  • Stock Option (right to buy)

    Exercise: $0.68Exp: 2022-12-05→ Common Stock, $0.001 par value per share (70,000 underlying)
    70,000

  • Series C-3 Non-Voting Convertible Preferred Stock

    Exercise: $1.00→ Common Stock, $0.01 par value per share (300,000 underlying)
    30,000
Footnotes (13)
  • [F1]Includes (i) 94,496 shares of our common stock held jointly by Dr. Gelbfish and his wife, and (ii) 70,872 shares of our common stock held by Dr. Gelbfish as custodian for certain of his children.
  • [F10]These options vested on January 14, 2012.
  • [F11]These options vest as follows: 1/3 on March 30, 2010, an additional 1/3 on March 30, 2011, and the remaining 1/3 on March 30, 2012.
  • [F12]These warrants became exercisable upon the consummation of the Company's initial public offering.
  • [F13]Includes 8% Noteholder Warrants held by Dr. Gelbfish and his wife jointly, that are exercisable for 38,400 shares of common stock, and 8% Noteholder Warrants held by Dr. Gelbfish as custodian for certain of his children that are exercisable for 28,800 shares of common stock.
  • [F2]Held by Landmark Foundation, of which Dr. Gelbfish and his wife are trustees.
  • [F3]The options vested 100% on January 10, 2014.
  • [F4]The options vest in full on the first anniversary of the date of grant.
  • [F5]On January 8, 2014, the reporting person acquired in a private placement (i) 30,000 shares of the Company's Series C-3 Non-Voting Convertible Preferred Stock, each share is convertible into 10 shares of Common Stock, $0.001 par value per share at a conversion price of $1.00 per share; and (ii) a five-year warrant to purchase common stock at an exercise price of $1.25 per share. The Series C-3 Preferred Stock and the warrants were purchased together at a price of $10.00 per share for each share of Series C-3 Preferred Stock.
  • [F6]On January 8, 2014, the reporting person through his ownership of his IRA account, acquired in a private placement (i) 20,000 shares of the Company's Series C-3 Non-Voting Convertible Preferred Stock, each share is convertible into 10 shares of Common Stock, $0.001 par value per share at a conversion price of $1.00 per share, and (ii) a five-year warrant to purchase common stock at an exercise price of $1.25 per share. The Series C-3 Preferred Stock and the warrants were purchased together at a purchase price of $10.00 per share for each share of Series C-3 Preferred Stock.
  • [F7]These options vest quarterly over two years beginning June 30, 2013.
  • [F8]These options vest as follows: (a) fifty percent (50%) on the date of the issuance of the CE Mark certification for Neutrolin in Europe, which occurred on July 5, 2013, and (50%) on December 31, 2013.
  • [F9]On September 20, 2012, the reporting person acquired in a private placement $100,000 of (i) 9% Senior Convertible Notes, convertible into shares of the Company's Common Stock, $0.001 par value per share, at a conversion price of $0.35 per share, which were converted on September 20, 2013; and (ii) a five-year redeemable warrant to purchase common stock at an exercise price of $0.40 per share.

Documents

1 file

Issuer

CorMedix Inc.

CIK 0001410098

→
Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001410098

Filing Metadata

Form type
4
Filed
Jan 13, 7:00 PM ET
Accepted
Jan 14, 4:12 PM ET
Size
28.0 KB
View on SEC.gov